Latest Long QT syndrome Stories
ROCHESTER, N.Y., Jan. 12 /PRNewswire-USNewswire/ -- Pfizer Inc. has agreed to provide the University of Rochester Medical Center (URMC) with a unique set of electrocardiographic data that will help researchers develop new methods to ensure the safety of experimental drugs.
Clinical Data, a biotechnology company, has announced that its PGxHealth division has launched a new genetic test for arrhythmogenic right ventricular cardiomyopathy, an inherited and often fatal heart condition.
U.S. and German researchers using a new animal model of genetic mutations say they've discovered some common anesthetics trigger arrhythmias in humans.
PGxHealth(R), a division of Clinical Data, Inc. (NASDAQ: CLDA), announced today that it has become an in-network provider with Aetna for healthcare coverage of its FAMILION(R) family of genetic tests.
OBS Medical announced today the successful completion of a cardiac safety analysis in support of a pharmaceutical sponsor's prospective drug study. BioQT(TM) is an advanced signal processing technique developed by OBS Medical.
By Walker, Dennis D Johnson, Monica L; Craig-Gray, Robert W; Loyd, Frank ABSTRACT Introduction: Brugada syndrome describes a subgroup of patients at risk for polymorphic ventricular tachycardia, ventricular fibrillation, and sudden cardiac death and is likely underdiagnosed among aviators.
PALO ALTO, Calif., Aug. 19 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc.
By Erdogan, Okan Aksoy, Alper; Turgut, Nilda; Durusoy, Elcim; Samsa, Murat; Altun, Armagan Abstract Andersen-Tawil syndrome (ATS) is a rare, heterogeneous, autosomal dominant, or sporadic disorder characterized by the clinical triad of periodic paralysis, dysmorphic features, and ventricular arrhythmias such as bidirectional ventricular tachycardia (BVT).
The Sudden Arrhythmia Death Syndromes (SADS) Foundation launched an awareness campaign through the second annual Climb to Conquer SADS event, taking place this week from July 9 through the 12th at Mount Rainier National Park in Washington state.
ARYx Therapeutics, Inc., (NASDAQ:ARYX), a biopharmaceutical company, today announced the results of an important cardiac safety study on its prokinetic agent, ATI-7505.